11/26
06:43 am
avbp
ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at Truist Financial Corporation to a "strong-buy" rating.
Low
Report
ArriVent BioPharma (NASDAQ:AVBP) was upgraded by analysts at Truist Financial Corporation to a "strong-buy" rating.
11/25
08:44 am
avbp
ArriVent BioPharma (NASDAQ:AVBP) was given a new $43.00 price target on by analysts at Truist Financial Corporation.
Low
Report
ArriVent BioPharma (NASDAQ:AVBP) was given a new $43.00 price target on by analysts at Truist Financial Corporation.
11/11
03:35 pm
avbp
ArriVent BioPharma (NASDAQ:AVBP) had its price target lowered by analysts at Citigroup Inc. from $33.00 to $31.00. They now have a "buy" rating on the stock.
Low
Report
ArriVent BioPharma (NASDAQ:AVBP) had its price target lowered by analysts at Citigroup Inc. from $33.00 to $31.00. They now have a "buy" rating on the stock.
11/10
08:18 am
avbp
ArriVent BioPharma Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
Low
Report
ArriVent BioPharma Reports Third Quarter 2025 Financial Results [Yahoo! Finance]
11/10
08:00 am
avbp
ArriVent BioPharma Reports Third Quarter 2025 Financial Results
Low
Report
ArriVent BioPharma Reports Third Quarter 2025 Financial Results
10/3
03:30 pm
avbp
ArriVent BioPharma (NASDAQ:AVBP) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
ArriVent BioPharma (NASDAQ:AVBP) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/22
04:05 pm
avbp
ArriVent Appoints Brent S. Rice as Chief Commercial Officer
Low
Report
ArriVent Appoints Brent S. Rice as Chief Commercial Officer
9/9
08:28 am
avbp
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer [Yahoo! Finance]
Low
Report
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer [Yahoo! Finance]
9/9
08:00 am
avbp
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer
Low
Report
Arrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung Cancer